Hillevax
IPO
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- hillevax.com
- Total Funding
- $136.3M
- Last Round
- $135.0M Series DSep 2021
About
Clinical-stage biopharmaceutical developing HIL-214, a virus-like-particle norovirus vaccine for infants and other at-risk populations.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account